Delivery Order SPE2DR25D3021-SPE2DR26FS8LS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $8,769.12, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $1,139.18, with an ultimate completion date of August 27, 2025. This non-set-aside, firm fixed price delivery order represents a competitively awarded procurement to supply vaccines supporting federal medical supply chain requirements. The contract is a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a $1,139.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits, with a completion deadline of July 14, 2025. This competitively awarded contract, issued on July 11, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $3,417.51 firm fixed price delivery order to AmerisourceBergen Drug Corp for SHINGRIX vial kits, with an ultimate completion date of May 28, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. SHINGRIX, a recombinant zoster vaccine, is a critical preventive health...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $51,263.00 to supply Shingrix vial kits, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion through December 2026. The contract carries no set-aside designation and will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits on November 20, 2025, with a ceiling value of $1,918.75 and an ultimate completion date of November 21, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed price pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency awarded a delivery order valued at $4,779.14 to AmerisourceBergen Drug Corp for Shingrix vial kits, with a completion date of July 22, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The work will be performed at the contractor's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Shingrix vial kits valued at $1,139.18, with an ultimate completion date of August 25, 2025. This competitive, firm fixed price delivery order was issued on August 22, 2025, with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across the Department of Defense and other...
- The Defense Logistics Agency awarded a delivery order valued at $11,391.80 to AmerisourceBergen Drug Corp for the supply of Shingrix vial kits, with a completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 through December 2026. The delivery will be fulfilled from the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,278.36 to AmerisourceBergen Drug Corp for Shingrix vial kits, with a completion date of September 8, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor will perform...
- SPE2DR25D3021Indefinite Delivery Contract
- SPE2DR25D3021-SPE2DR26FS8LSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,723.40 to AmerisourceBergen Drug Corp for Shingrix vial kits, with an ultimate completion date of December 4, 2025. This firm fixed price contract, awarded on December 3, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award utilized no set-aside designation and was competitively awarded. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. This delivery order fulfills medical supply requirements under DLA's comprehensive pharmaceutical support vehicle, which enables AmerisourceBergen to supply vaccines, medications, and medical commodities to support military healthcare programs globally. Shingrix, a recombinant zoster vaccine, represents the type of specialty pharmaceutical product within the company's broader portfolio of brand-name and generic drugs, vaccines, and medical supplies delivered across multiple therapeutic domains. The parent IDC supports various federal healthcare customers including the Defense Health Agency and U.S. Coast Guard, demonstrating AmerisourceBergen's established capability to meet federal medical procurement requirements through its extensive distribution and supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 12/2/25 |